Not recruiting yet
RATME Vs LATME in Middle and Low Rectal Cancer
NCT06105203 · The First Hospital of Jilin University · Updated 19 Feb 2025
- What is being tested
- Robotic-assisted total mesorectal excision; laparoscopic-assisted total mesorectal excision
- For
- Total Mesorectal Excision; Rectal Neoplasms; Robotic Surgical Procedures; Laparoscopy
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 75 years. About 1,026 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 1 Nov 2025, ends Jan 2031. Registered 27 Oct 2023.
- Results
- None posted yet.
In the researchers' words
This is a multicenter, superior, randomized controlled trial designed to compare Robotic-assisted total mesorectal excision (RATME) and laparoscopic-assisted total mesorectal excision (LATME) for middle and low rectal cancer. The primary endpoint is the incidence of intersphincteric resection (ISR). The secondary outcomes are coloanal anastomosis (CAA), conversion to open, conversion to transanal TME (TaTME), incidence of abdominoperineal resection (APR), postoperative morbidity and mortality within 30 days after surgery, pathological outcomes, long-term survival outcomes, functional outcomes, and quality of life.
Sites
- The First Hospital of Jilin UniversityChangchun, Jilin, China